Page last updated: 2024-08-23

pravastatin and torcetrapib

pravastatin has been researched along with torcetrapib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Einecke, D	1
Bots, ML; Doevendans, PA; Grobbee, DE; Jukema, JW; Kastelein, JJ; Kuivenhoven, JA; Regieli, JJ; van der Graaf, Y; Zwinderman, AH	1

Other Studies

2 other study(ies) available for pravastatin and torcetrapib

Article	Year
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?]. MMW Fortschritte der Medizin, 2006, Jun-15, Volume: 148, Issue:24 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional	2006
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. European heart journal, 2008, Volume: 29, Issue:22 Topics: Alleles; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Genotype; Humans; Male; Pharmacogenetics; Polymorphism, Genetic; Pravastatin; Predictive Value of Tests; Quinolines; Randomized Controlled Trials as Topic	2008

Article

Year

[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].

MMW Fortschritte der Medizin, 2006, Jun-15, Volume: 148, Issue:24

Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional

2006

CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.

European heart journal, 2008, Volume: 29, Issue:22

Topics: Alleles; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Genotype; Humans; Male; Pharmacogenetics; Polymorphism, Genetic; Pravastatin; Predictive Value of Tests; Quinolines; Randomized Controlled Trials as Topic

2008